ReviewFrontiers in endocrinology2022
Myoinositol in Autoimmune Thyroiditis.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Article
- Nanoparticles in Thyroid Autoimmunity: Diagnostic and Therapeutic Applications.Journal of clinical medicine · 2026Review
- Recent advances of trace elements in autoimmune thyroid disease.Frontiers in immunology · 2025Review
- Research Progress of Natural Killer Cells in Hashimoto's Thyroiditis.ImmunoTargets and therapy · 2025Review
- Article
- Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment.International journal of molecular sciences · 2024Review
- Exploring the potential of myo-inositol in thyroid disease management: focus on thyroid cancer diagnosis and therapy.Frontiers in endocrinology · 2024Review
- Thyroid dysfunction during gestation and gestational diabetes mellitus: a complex relationship.Journal of endocrinological investigation · 2023Review
- Global scientific trends on thyroid disease in early 21st century: a bibliometric and visualized analysis.Frontiers in endocrinology · 2023Article
- Thyroid hormones and minerals in immunocorrection of disorders in autoimmune thyroid diseases.Frontiers in endocrinology · 2023Review
- Selenium and thyroid diseases.Frontiers in endocrinology · 2023Review
- Polycystic ovary syndrome and thyroid disorder: a comprehensive narrative review of the literature.Frontiers in endocrinology · 2023Review
- The protective role of nutritional antioxidants against oxidative stress in thyroid disorders.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myoinositol (Myo) is an isoform of inositol, a cyclic polyol with 6 hydroxyl groups. Myo is mainly derived from dietary intake while its endogenous production is generated from glucose by enzymatic reactions. Moreover, Myo is also synthesized
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.